Literature DB >> 32792630

Clinical decision support tool for phototherapy initiation in preterm infants.

Yassar Arain1,2, Juan M Banda3,4, Joshua Faulkenberry5, Vinod K Bhutani1, Jonathan P Palma6,7.   

Abstract

OBJECTIVE: Adherence to guidelines for phototherapy initiation in preterm infants was 39% in our academic NICU (61% of phototherapy was initiated at total bilirubin (TB) levels below recommended thresholds). We hypothesized that adoption of an electronic health record integrated clinical decision support (CDS) tool would improve adherence to phototherapy guidelines. STUDY
DESIGN: We developed and implemented Premie BiliRecs (PBR), a novel CDS tool for phototherapy initiation in preterm infants from 27 through 34 weeks postmenstrual age. The primary outcome measure was the proportion of phototherapy initiation events consistent with recommended TB thresholds. RESULT: Following the implementation of PBR, adherence to guidelines for phototherapy initiation in preterm infants increased to 69.8% (p < 0.001), an improvement of 77%. There was no increase in the incidence of severe hyperbilirubinemia nor exchange transfusions.
CONCLUSION: The adoption of PBR was associated with improved adherence to phototherapy guidelines in preterm infants without increased adverse events.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32792630     DOI: 10.1038/s41372-020-00782-0

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  1 in total

1.  Development of a Web-based decision support tool to increase use of neonatal hyperbilirubinemia guidelines.

Authors:  Christopher Longhurst; Stuart Turner; Anthony E Burgos
Journal:  Jt Comm J Qual Patient Saf       Date:  2009-05
  1 in total
  2 in total

1.  Towards effective clinical decision support systems: A systematic review.

Authors:  Francini Hak; Tiago Guimarães; Manuel Santos
Journal:  PLoS One       Date:  2022-08-15       Impact factor: 3.752

Review 2.  Dose-Related Adverse Drug Events in Neonates: Recognition and Assessment.

Authors:  Karel Allegaert; John van den Anker
Journal:  J Clin Pharmacol       Date:  2021-06       Impact factor: 3.126

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.